Roegiers v. United States

CourtDistrict Court, D. Connecticut
DecidedSeptember 22, 2023
Docket3:21-cv-01034
StatusUnknown

This text of Roegiers v. United States (Roegiers v. United States) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Roegiers v. United States, (D. Conn. 2023).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT

OLIVIA ROEGIERS, PPA JEREMY : Case No. 3:21-cv-1034 (OAW) ROEGIERS AND KRISHNA ROEGIERS : Plaintiff : : v. : : UNITED STATES OF AMERICA : Defendant/Third-Party Plaintiff : : v. : : LAWRENCE AND MEMORIAL : HOSPITAL, INC.; GAUTHAMI SOMA, : M.D. : Third-Party Defendants :

OMNIBUS RULING

THIS ACTION is before the court upon two motions: 1) Motion to Dismiss the Government’s Apportionment Complaint, ECF No. 28; and 2) Third-Party Defendants’ Motion to Dismiss, ECF No. 37. With regard to each, the court has reviewed the motions themselves, ECF No. 28, 37, the respective parties’ opposition thereto, ECF No. 33, 38, and Third-Party Defendants’ replies to Plaintiff’s oppositions, ECF No. 36, 41, as well as the record in this case. For the reasons discussed herein, the motions are GRANTED. Plaintiff Olivia Roegiers, through her parents Jeremy and Krishna Roegiers (“Plaintiff”), brought this medical malpractice action against the United States of America (“government”), pursuant to the Federal Tort Claims Act (“FTCA”), 28 U.S.C. §§ 1346 et seq., alleging injuries sustained as a result of negligence by a federal naval clinic doctor. See Compl., ECF No. 1. In response, the government has named Lawrence & Memorial Hospital (“Hospital”) and Dr. Gauthami Soma, M.D. (“Dr. Soma”) as third-party defendants (together, “Defendants”).1 See Third Party Compl., ECF No. 17. Defendants have moved to dismiss the government’s third-party apportionment complaint for lack of personal jurisdiction pursuant to Federal Rule of Civil Procedure 12(b)(2). See Third-Party Def.’s Mot. to Dismiss, ECF No. 28.

Subsequent to the government’s third-party complaint, Plaintiff separately filed a complaint against Defendants. See Pl.’s Claim Against Third Party Def., ECF No. 30. Defendants have moved to dismiss Plaintiff’s claim for untimeliness, pursuant to Federal Rule of Civil Procedure 12(b)(6). See Third-Party Defs.’ Mot. to Dismiss, ECF No. 37.

I. BACKGROUND On September 10, 2018, Plaintiff Olivia Roegiers was born at the Hospital in New London, Connecticut. Compl. at Facts ¶ 1, ECF No. 1. She was discharged on September 12, 2018; at that time, she had a total bilirubin level of 8.8 mg/dL and a direct bilirubin level of 2.0 mg/dL.2 Id. at ¶ 2. The next day (on September 13, 2018),

pediatrician and federal employee, Dr. Christina Toufexis, M.D., examined Plaintiff at the federal Navy Health Clinic in Groton, Connecticut (“Naval Clinic”). Id. at ¶¶ 3–4. At that examination, Plaintiff reportedly had a total bilirubin level of 10.4 mg/dL, and her skin showed no jaundice. Id. at ¶ 6. On September 27, 2018, Dr. Toufexis again examined Plaintiff, and again reported no signs of jaundice. Id. at ¶ 7.

1 The court notes that the Hospital and Dr. Soma are third-party defendants while the government is the named defendant and third-party plaintiff. For ease of reference throughout this ruling, however, the court will refer to the Hospital and Dr. Soma as “Defendants.” 2 Bilirubin is a byproduct that is made during the breakdown of red blood cells. See Bilirubin Test, Mayo Clinic, https://www.mayoclinic.org/tests-procedures/bilirubin/about/pac-20393041 [https://perma.cc/Q7JG- P7EJ] (last visited Sept. 15, 2023). Usually, bilirubin levels are tested in order to check the health of the liver, as high bilirubin levels can indicate liver disease or damage. Id. Elevated bilirubin can produce jaundice (a yellowing of the skin or eyes). Id. The next time Plaintiff was seen by Dr. Toufexis was on November 13, 2018. Id. at ¶ 8. A notation of “+jaundice” was made at this visit, and Dr. Toufexis ordered exams for unspecified jaundice with a note to follow up about the results of the lab tests. Id. On November 21, 2018, Plaintiff went to the Hospital laboratory, and left with a visit diagnosis

of chronic cholestatic jaundice syndrome. Id. at ¶ 9. The results of Plaintiff’s lab tests showed a total bilirubin level of 8.2 mg/dL and a direct bilirubin level of 6.91 mg/dL. Id. at ¶ 10. Dr. Toufexis’s office received the lab results on November 23, 2018. Id. at ¶ 11. There was no documented follow-up to Plaintiff’s family by Dr. Toufexis or the Naval Clinic about the lab results, or the findings from the November 13, 2018, exam. Id. at ¶ 11. Plaintiff was not seen again by Dr. Toufexis until a well-check visit on January 23, 2019, more than two months after her prior exam. Id. at ¶ 12. At this visit, Plaintiff’s mother was concerned about an extended belly and belly button pushing out for two weeks. Id. Dr. Toufexis conducted an exam which revealed the following: “eyes: +icterns; skin: no jaundice; abdomen: distended, soft, non-tender; umbilical hernia discovery 1 cm

reducible.” Id. Plaintiff’s bilirubin TCB was noted to be 7.6 mg/dL.3 Plaintiff was immediately referred to Hasbro Children’s Hospital (“Children’s Hospital”). Id. at ¶ 13. At the Children’s Hospital, intake documentation noted that Plaintiff had been referred by her primary-care physician’s office based on increasing abdominal distention, jaundice, and the lab results from November 21, 2018, that showed the following: Alk phos 331, Alt 330, AST 359, total bilirubin 10.4, direct bilirubin 6.91, and albumin 2.7. Id. at ¶ 14. Plaintiff’s mother did not know about the lab results from November 21, 2018,

3 TCB, or transcutaneous bilirubin measurement, is another way to measure bilirubin levels in infants. What are Jaundice and Kernicterus?, CDC, https://www.cdc.gov/ncbddd/jaundice/facts.html [https://perma.cc/ 7T8P-ZFV2] (last visited Sept. 15, 2023). This method involves checking a baby’s bilirubin levels by using a light meter that is placed on the baby’s head. Id. until January 23, 2019. Id. On January 24, 2019, Plaintiff began a liver transplant evaluation, which continued at Yale-New Haven Hospital; there, she underwent additional testing. Id. at ¶ 15. Eventually, Plaintiff was approved for a liver transplant, and she underwent surgery on or about November 1, 2020. Id.

Plaintiff alleges that Dr. Toufexis was negligent at various phases: in failing to refer Plaintiff to a pediatric gastroenterologist or pediatric liver transplant specialist; in failing to follow up with Plaintiff’s family regarding the findings of jaundice or the lab results; and in failing to promptly investigate the possible diagnosis of biliary atresia.4 Id. at ¶ 16. Plaintiff alleges that she was not properly evaluated, diagnosed (with biliary atresia), or treated (using the “Kasai” procedure5). Id. at ¶ 17. Additionally, Plaintiff alleges that, had Dr. Toufexis acted according to the standard of care, Plaintiff “probably would have been diagnosed in a timely fashion” so as to be afforded timely and necessary treatment (such as, with the Kasai procedure), which would have eliminated the need for the immediate liver transplant that ultimately, she had to undergo. Id. at ¶ 18.

On July 28, 2021, Plaintiff filed the instant medical malpractice action against the government. On June 30, 2022, the government filed a third-party complaint, asserting two counts for apportionment toward the Hospital and Dr. Soma. See Third-Party Compl., ECF No. 17. This apportionment complaint alleged that because Plaintiff was born at the Hospital, where she had bloodwork taken that indicated elevated direct bilirubin levels, and where she was discharged without any additional testing, follow-up medical care, or

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Bruce Ball v. Metallurgie Hoboken-Overpelt, S.A.
902 F.2d 194 (Second Circuit, 1990)
Andrulonis v. United States
26 F.3d 1224 (Second Circuit, 1994)
In Re Magnetic Audiotape Antitrust Litigation
334 F.3d 204 (Second Circuit, 2003)
Thomas v. Ashcroft
470 F.3d 491 (Second Circuit, 2006)
Graziano v. Pataki
689 F.3d 110 (Second Circuit, 2012)
MacDermid, Inc. v. Deiter
702 F.3d 725 (Second Circuit, 2012)
Carpenter v. Law Offices of Dressler & Associates, LLC
858 A.2d 820 (Connecticut Appellate Court, 2004)
Chirag v. MT Marida Marguerite Schiffahrts
604 F. App'x 16 (Second Circuit, 2015)
Conn. Gen. Life Ins. Co. v. BioHealth Labs., Inc.
988 F.3d 127 (Second Circuit, 2021)
Corley v. United States
11 F.4th 79 (Second Circuit, 2021)
Lostritto v. Community Action Agency of New Haven, Inc.
848 A.2d 418 (Supreme Court of Connecticut, 2004)
Nielsen v. AECOM Technology Corp.
762 F.3d 214 (Second Circuit, 2014)
Estate of Nobile v. United States
193 F.R.D. 58 (D. Connecticut, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
Roegiers v. United States, Counsel Stack Legal Research, https://law.counselstack.com/opinion/roegiers-v-united-states-ctd-2023.